INHIBITION OF HUMAN 5-PHOSPHORIBOSYL-1-PYROPHOSPHATE SYNTHETASE BY 4-AMINO-8-(BETA-D-RIBOFURANOSYLAMINO)PYUIMIDO[5,4-D]PYRIMIDINE-5'-MONOPHOSPHATE - EVIDENCE FOR INTERACTION AT THE ADP ALLOSTERIC SITE

被引:0
|
作者
FRY, DW
BECKER, MA
SWITZER, RL
机构
[1] UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA
[2] UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The kinetics of inhibition by the aminopyrimidopyrimidine nucleotide 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyri midine-5'-monophosphate (APP-MP) were assessed with two human isozymes of 5-phosphoribosyl-1-pyrophosphate synthetase (PRS) (PRS1 and PRS2) and a mutant enzyme, S.M. PRS1, derived from an individual with PRS hyperactivity. In the presence of 1 mM potassium phosphate, APP-MP inhibited PRS1 and PRS2 with half-maximal inhibition (IC50) at 5.2 mu M and 23.8 mu M, respectively. The degree of inhibition for both enzymes was highly dependent on the phosphate concentration; IC50 values were 70 times higher in the presence of 50 mM potassium phosphate. APP-MP exhibited mixed noncompetitive-uncompetitive inhibition against PRS1, with a K-il value of 6.1 mu M and a K-is value of 14.6 mu M, and produced parabolic secondary plots of slope or intercept versus APP-MP concentration. In comparison, inhibition of PRS1 by ADP was of a mixed noncompetitive-competitive type, with a K-il value of 9.6 mu M and a K-is value of 2.8 mu M. A similar kinetic analysis was completed using S.M. PRS1, a mutant enzyme with a single amino acid substitution resulting in diminished sensitivity to feedback inhibition by nucleotides. The noncompetitive component of ADP inhibition of PRS1 was absent with S.M. PRS1 and ADP inhibition was purely competitive, with a K-i of 6.4 mu M. APP-MP was a very poor inhibitor of S.M. PRS1, displaying uncompetitive characteristics and a K-i of 1.6 mM. These data indicate that APP-MP inhibits PRS1 with a strong element of noncompetitive inhibition and appears to interact specifically at the allosteric site used by ADP. These results contrast with those obtained with ADP, which has a strong component of ATP competitive inhibition and binds at the ATP site as well as at a second, allosteric, site.
引用
收藏
页码:810 / 815
页数:6
相关论文
共 14 条
  • [1] INHIBITION OF 5-PHOSPHORIBOSYL-1-PYROPHOSPHATE SYNTHETASE BY THE MONOPHOSPHATE METABOLITE OF 4-AMINO-8-(BETA-D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE - A NOVEL MECHANISM FOR ANTITUMOR-ACTIVITY
    FRY, DW
    BORITZKI, TJ
    JACKSON, RC
    COOK, PD
    LEOPOLD, WR
    MOLECULAR PHARMACOLOGY, 1993, 44 (02) : 479 - 485
  • [2] INHIBITION OF PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE BY 4-METHOXY-8-(D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE (MRPP) AND 4-AMINO-8-(D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE (ARPP)
    NORD, LD
    WILLIS, RC
    BREEN, TS
    AVERY, TL
    FINCH, RA
    SANGHVI, YS
    REVANKAR, GR
    ROBINS, RK
    BIOCHEMICAL PHARMACOLOGY, 1989, 38 (20) : 3543 - 3549
  • [3] INHIBITION OF PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE BY THE ANTITUMOR NUCLEOSIDE 4-AMINO-8-(D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE (ARPP)
    NORD, LD
    BREEN, T
    WILLIS, RC
    AVERY, TL
    ROBINS, RK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 17 - 17
  • [4] STRUCTURAL STUDIES OF THE NOVEL ANTITUMOR AGENTS 4-AMINO-8-(BETA-D-RIBOFURANOSYLAMINO)PYRIMIDO(5,4-D) PYRIMIDINE AND 4-METHOXY-8-(BETA-D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE AND THEIR ALPHA-ANOMERS USING X-RAY, H-1-NMR, AND THEORETICAL METHODS
    GHOSE, AK
    SANGHVI, YS
    LARSON, SB
    REVANKAR, GR
    ROBINS, RK
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1990, 112 (09) : 3622 - 3628
  • [5] INHIBITION OF PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE BY 4-AMINO-8-(D-RIBOFURANSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE (ARPP)
    WILLIS, RC
    BREEN, T
    NORD, LD
    FASEB JOURNAL, 1988, 2 (05): : A1349 - A1349
  • [6] STRUCTURAL MIMICRY OF ADENOSINE BY THE ANTITUMOR AGENTS 4-METHOXY AND 4-AMINO-8-(BETA-D-RIBOFURANOSYLAMINO)PYRIMIDO-[5,4-D]PYRIMIDINE AS VIEWED BY A MOLECULAR MODELING METHOD
    GHOSE, AK
    VISWANADHAN, VN
    SANGHVI, YS
    NORD, LD
    WILLIS, RC
    REVANKAR, GR
    ROBINS, RK
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) : 8242 - 8246
  • [7] CYTOTOXICITY AND METABOLISM OF 4-METHOXY-8-(BETA-D-RIBOFURANOSYLAMINO)PYRIMIDO[5,4-D]PYRIMIDINE IN HCT-116 COLON-CANCER CELLS
    GREM, JL
    DAYCHILD, P
    DRAKE, J
    GEOFFROY, F
    TREPEL, JB
    PIRNIA, F
    ALLEGRA, CJ
    BIOCHEMICAL PHARMACOLOGY, 1994, 48 (11) : 2117 - 2126
  • [8] BIOCHEMICAL PHARMACOLOGY AND ANTITUMOR PROPERTIES OF 4-AMINO-8-[BETA-D-RIBO-FURANOSYLAMINO]PYRIMIDO-[5,4-D]PYRIMIDINE
    JACKSON, RC
    BORITZKI, TJ
    COOK, PD
    HOOK, KE
    LEOPOLD, WR
    FRY, DW
    ADVANCES IN ENZYME REGULATION, 1989, 28 : 185 - 199
  • [9] BIOCHEMICAL PHARMACOLOGY AND ANTITUMOR PROPERTIES OF 4-AMINO-8-[BETA-D-RIBO-FURANOSYLAMINO]PYRIMIDO-[5,4-D]PYRIMIDINE
    JACKSON, RC
    BORITZKI, TJ
    COOK, PD
    HOOK, KE
    LEOPOLD, WR
    FRY, DW
    ADVANCES IN ENZYME REGULATION, VOL 28, 1989, 28 : 185 - 199
  • [10] A Mild Approach to the Synthesis of 4-Amino-8-(arylamino)pyrimido[5,4-d]pyrimidine 3-Oxides
    Ribeiro, Alexandra
    Carvalho, M. Alice
    Proenca, M. Fernanda
    EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2009, 2009 (28) : 4867 - 4872